| 18:00 - 18:30 |
Registration, tea and coffee
|
| 18:30 - 18:40 |
Welcome from One Nucleus and RVC/LBIC
Tony Jones and Professor Jonathan Elliott
|
| 18:40 - 18:55 |
Optimising animal studies: An industrial perspective
Dr Jonathan Kearsey, Leads To Development
Novel therapeutic approaches offer high promise but require optimised efficacy and safety studies that are specifically tailored to each programme. This presentation will focus on the oncology field and will outline the essential experiments required to demonstrate both efficacy and therapeutic value from an industrial perspective. Recent examples of preclinical studies that have or have not led to successful clinical therapies will be reviewed.
|
| 18:55 - 19:20 |
An ideal model? The use of naturally occurring models of disease in biomedical research. Dr Imelda McGonnell, RVC
Animal models are invaluable for biomedical researchers in understanding the pathobiology of disease and to test new therapeutic approaches. The majority of animals used in research are rodents, with fish models becoming increasingly popular. Typically, these models have an induced disease, for example through gene manipulation, that may not fully resemble complex human disease. Naturally occurring animal models have significant benefits for the biomedical research community as the typical have similar disease induction and follow similar disease progression to the human. Here we will discuss a number of naturally occurring animal models used at the RVC, in particular the dog model of osteosarcoma, to demonstrate the potential these models have for identifying new therapeutic targets
.
|
| 19:20 – 19:35 |
Role of Zebrafish indrug discovery and development
Dr Mohammed Yaqoob
For early drug discovery and during preclinical testing such as toxicity and safety assessment there is increasing demand to minimize on use of animals to situations in which they are absolutely necessary. Zebrafish can play a pivotal role at various stages of the drug discovery process and can be a useful and cost-effective substitute to some mammalian models. We will discuss the role of zebrafish in drug discovery and development in terms of toxicity and efficacy models of zebrafish available at Pharmidex that can limit use of larger animals and significant reduction on quantity of precious compounds required during drug discovery and development.
|
| 19:35 – 19:45 |
Final comments and wrap up
Tony Jones, Director of Business Development, One Nucleus
|
| 19:45 – 21:00 |
Posters, exhibit stands, drinks, light refreshments and networking
|